1. CAR T cells in marginal zone lymphoma (MZL) models with acquired resistance to PI3K and BTK inhibitors. (October 2022) Authors: Wang, S.; Arribas, A.J.; Tarantelli, C.; Pradier, A.; Zucca, E.; Rossi, D.; Simonetta, F.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S106 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. (8th March 2016) Authors: Gaudio, E.; Tarantelli, C.; Kwee, I.; Barassi, C.; Bernasconi, E.; Rinaldi, A.; Ponzoni, M.; Cascione, L.; Targa, A.; Stathis, A.; Goodstal, S.; Zucca, E.; Bertoni, F. Journal: Annals of oncology Issue: Volume 27:Number 6(2016:Jun.) Page Start: 1123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. COMBINATORIAL SCREENING OF THE PI3K INHIBITOR COPANLISIB IN T CELL LYMPHOMAS. (June 2017) Authors: Gaudio, E.; Kwee, I.; Spriano, F.; Tarantelli, C.; Rinaldi, A.; Jourdan, T.; Berthold, M.; Arribas, A.; Stathis, A.; Rossi, D.; Liu, N.; Lange, M.; Politz, O.; Zucca, E.; Bertoni, F. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 256 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B‐ AND T‐CELL LYMPHOMAS. (12th June 2019) Authors: Tarantelli, C.; Lange, M.; Gaudio, E.; Cascione, L.; Spriano, F.; Kwee, I.; Arribas, A.; Rinaldi, A.; Jourdan, T.; Berthold, M.; Margheriti, F.; Gritti, G.; Rossi, D.; Stathis, A.; Liu, N.; Zucca, E.; Politz, O.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. DEVELOPMENT OF NOVEL PRECLINICAL MODELS OF SECONDARY RESISTANCE TO THE PI3KΔ INHIBITOR IDELALISIB IN SPLENIC MARGINAL ZONE LYMPHOMA (SMZL). (June 2017) Authors: Arribas, A.J.; Gaudio, E.; Rinaldi, A.; Cascione, L.; Tarantelli, C.; Kwee, I.; Stathis, A.; Zucca, E.; Rossi, D.; Bertoni, F. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. EG‐011 IS A NOVEL SMALL MOLECULE WITH IN VITRO AND IN VIVO ANTI‐TUMOR ACTIVITY AGAINST LYMPHOMA. (12th June 2019) Authors: Gaudio, E.; Spriano, F.; Tarantelli, C.; Guala, M.; Riveiro, E.; Golino, G.; Lupia, A.; Costa, G.; Rocca, R.; Cascione, L.; Jenni, S.; Tsai, Y.; Bornhauser, B.; Alcaro, S.; Paduano, F.; Trapasso, F.; Zucca, E.; Stathis, A.; Pazzi, N.; Cavalli, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 513 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Improving responses to dual PI3K/BCL2 inhibition in lymphomas: results of a pharmacological screen with over 1, 400 compounds. (October 2022) Authors: Arribas, A.; Chiappa, M.; Napoli, S.; Cannas, E.; Cascione, L.; Spriano, F.; Tarantelli, C.; Rossi, D.; Zucca, E.; Alimonti, A.; Stathis, A.; Damia, G.; Broggini, M.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. MECHANISMS OF SECONDARY RESISTANCE TO IDELALISIB IN MARGINAL ZONE LYMPHOMA. (12th June 2019) Authors: Arribas, A.; Napoli, S.; Gaudio, E.; Cascione, L.; Di Veroli, A.; Tarantelli, C.; Spriano, F.; Zucchetto, A.; Rossi, F.; Rinaldi, A.; Stathis, A.; Stussi, G.; Gattei, V.; Cruciani, G.; Zucca, E.; Rossi, D.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 319 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. N-1, 2, 3-Triazole-Isatin derivatives in lymphoma cell lines. (October 2022) Authors: Gaudio, E.; Tarantelli, C.; Marques, C.S.; Ekeh, H.; Carmelo, M.; Burker, A.J.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Non-ATP competitive inhibition of PI3Kδ with IOA-244 shows anti-lymphoma activity. (October 2022) Authors: Tarantelli, C.; Spriano, F.; Cascione, L.; Civanelli, E.; Cannas, E.; Mensah, A.A.; Arribas, A.J.; Rinaldi, A.; Stathis, A.; Di Conza, G.; Niewola-Staszkowska, K.; Lahn, M.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S80 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗